Year: 2024
Type: conference-abstract
Abstract: Electronic poster abstractsand selection process, 56 were included.Our dichotomous outcomes were pooled in our single-arm meta-analysis as risk ratio (RR) and with 95% confidence interval (CI) while our continuous outcomes were pooled as mean change (MC) and 95% CI.The fixed-effects or random-effects model, were applied depending on heterogeneity detected.Results: Our systematic review included 56 studies encompassing 11740 patients.Depending on the Society Of Interventional Radiology (SIR) classification for adverse effects.The results of this meta-analysis for the Type A category which did not need clinical intervention found that pain in the treatment site estimated RR with 95% CI: 0.61[0.33,0.89],Abnormal Vaginal discharge 0.16[0.073,0.24], Low-grade fever (<38 • C) 0.005[0.002,0.009].Sensory abnormalities of the lower limbs were examined in 3390 individuals and observed in only 19 patients with gradual relief of symptoms within one month after treatment.As regards SIR Type (B) 99 patients of a total 6437 patients had small vesicles and superficial with pooled RR and 95%CI: 0.012 [0.007, 0.018].However, vaginal bleeding was only detected in 32 cases of a total of 3017.Major adverse events were unmentionable, Also Our included studies did not record any deaths at all.Conclusions: Current evidence shows that HIFU is safe for patients with different gynecological and obstetric diseases.To our knowledge, we are the first and the most comprehensive meta-analysis in the literature that studied the different safety outcomes related to HIFU as a treatment modality for different obstetric and gynecological diseases with a very large sample size, making our evidence strong.
DOI: 10.1002/uog.29016
Authors: G. Szabó, C. Culcasi, E. Gatti, Z.Y. Ng, L. Zanchi, D. Fischerová
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402358774